TD Waterhouse Canada Inc. Buys 2,855 Shares of Quest Diagnostics Incorporated $DGX

TD Waterhouse Canada Inc. grew its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 7.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,195 shares of the medical research company’s stock after buying an additional 2,855 shares during the period. TD Waterhouse Canada Inc.’s holdings in Quest Diagnostics were worth $7,145,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC lifted its holdings in shares of Quest Diagnostics by 114.3% during the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 80 shares in the last quarter. True Wealth Design LLC lifted its holdings in shares of Quest Diagnostics by 369.7% during the 3rd quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 122 shares in the last quarter. Harbor Investment Advisory LLC lifted its holdings in shares of Quest Diagnostics by 113.7% during the 4th quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 83 shares in the last quarter. First Horizon Corp bought a new position in shares of Quest Diagnostics during the 3rd quarter valued at about $33,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Quest Diagnostics during the 3rd quarter valued at about $33,000. Institutional investors own 88.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Truist Financial lifted their price objective on Quest Diagnostics from $205.00 to $220.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Robert W. Baird set a $219.00 price objective on Quest Diagnostics in a report on Wednesday, February 11th. Citigroup lifted their price objective on Quest Diagnostics from $190.00 to $215.00 and gave the company a “neutral” rating in a report on Tuesday, February 10th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Quest Diagnostics in a report on Monday, December 29th. Finally, Evercore set a $225.00 price objective on Quest Diagnostics in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $212.23.

Insider Transactions at Quest Diagnostics

In other Quest Diagnostics news, EVP Catherine T. Doherty sold 5,558 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total value of $1,146,115.18. Following the sale, the executive vice president owned 67,122 shares in the company, valued at approximately $13,841,227.62. The trade was a 7.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Karthik Kuppusamy sold 2,628 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $204.86, for a total value of $538,372.08. Following the completion of the sale, the senior vice president owned 13,441 shares in the company, valued at $2,753,523.26. The trade was a 16.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 24,083 shares of company stock worth $4,945,262. 8.16% of the stock is currently owned by insiders.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Q1 results beat and guidance raised — Quest reported adjusted EPS of $2.50 and revenue of $2.90B (≈+9.2% y/y) and raised FY‑2026 adjusted EPS to $10.63–$10.83 and revenue to ~$11.8–$11.9B, a clear catalyst for the stock moving higher. Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Growth drivers called out — Coverage notes organic volume strength in routine diagnostic testing plus new partnerships and AI tools helped revenue and margin performance, supporting the higher outlook. Quest Diagnostics Gains Steam With Partnerships, Lifts Outlook
• Positive Sentiment: Wall Street reaction and analyst context — Several analysts and outlets emphasize the beat + guide as validation of execution; some firms maintain/raise targets and at least one recent buy rating is on record, supporting near‑term investor interest. Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX)…
• Neutral Sentiment: Earnings details and management commentary available — The earnings press release, slide deck and full earnings‑call transcript provide the specifics behind the beat and guidance for investors who want to vet margin drivers and segment performance. Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Insider and institutional activity flagged — Data aggregators note sizable insider sales and notable institutional position reductions in recent quarters; while not tied to the quarter’s operational outlook, these flows could add selling pressure or limit upside for some investors. Quest Diagnostics rises after Q1 earnings beat and higher 2026 outlook

Quest Diagnostics Trading Up 4.5%

NYSE DGX opened at $205.12 on Wednesday. The stock has a market capitalization of $22.70 billion, a price-to-earnings ratio of 23.44, a PEG ratio of 2.54 and a beta of 0.66. The stock’s 50 day moving average price is $200.53 and its two-hundred day moving average price is $189.02. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.96 and a current ratio of 1.04. Quest Diagnostics Incorporated has a 52 week low of $164.65 and a 52 week high of $213.50.

Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.37 by $0.13. The firm had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.83 billion. Quest Diagnostics had a return on equity of 15.57% and a net margin of 8.99%.The business’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.94 EPS. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. As a group, analysts anticipate that Quest Diagnostics Incorporated will post 10.6 earnings per share for the current fiscal year.

Quest Diagnostics Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 20th. Shareholders of record on Monday, April 6th were paid a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.7%. The ex-dividend date was Monday, April 6th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s dividend payout ratio (DPR) is presently 39.31%.

Quest Diagnostics declared that its board has authorized a stock buyback program on Tuesday, February 10th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 4.7% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Quest Diagnostics Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.